Journal News

cAMP: Mapping a second messenger

How does protein phosphorylation contribute to localized cellular signaling?
Arti Dumbrepatil
Feb. 16, 2022

Cyclic adenosine 3,5-monophosphate, known as cAMP, acts as what the Nobel prize–winning neuroscientist Paul Greengard called a “second messenger” in regulating cellular functions such as growth and specialization, protein expression, and gene transcription by relaying extracellular signals to the cell’s interior.

In disease, intracellular pathways control cytokine secretion, resistance to toxins and pathological events by balancing the activity of enzymes, which adjust intracellular cAMP levels. Researchers recently have recognized that receptors can regulate cAMP production not only from the cell surface but also from intracellular membranes.

cAMP can diffuse rapidly, but under normal conditions, its concentration varies from place to place within a cell. It can cause highly localized downstream effects, suggesting that cellular compartmentalization underlines selective cellular responses. To investigate the impact of cAMP production when initiated from endocytic vesicles, a team led by Nikoleta Tsvetanova of Duke University and Mark von Zastrow of the University of California, San Francisco, used localized optical stimulation of cAMP synthesis and quantitative mass spectrometry to determine how compartmentalized cAMP production impacts downstream responses assessed through protein phosphorylation. Their study was published in the Journal of Biological Chemistry.

Tsvetanova et al./Journal of Biological Chemistry
cAMP signaling induces profound changes in the cellular phosphoproteome. Here, subcellular localization of bPAC constructs are visualized by immunofluorescence microscopy with Alexa-conjugated anti-myc antibody in fixed cells. Scale bar = 10 μm.

“We sought to determine the overall functional significance of generating cAMP from internal membranes relative to the plasma membrane,” von Zastrow said.

The researchers seek to delineate the fundamental principles by which cells and tissues mount physiologically appropriate responses to a range of external and internal chemical inputs. They also are investigating the cellular basis of receptor-mediated drug action to identify paths for improving therapeutic efficacy.

“The first main takeaway is that generating cAMP from endosomes has widespread downstream effects,” von Zastrow said. “We initially thought we’d see only a small number of differences, but we identified many changes in the cellular phosphoproteome that result from endosome-generated cAMP relative to cAMP generated from the plasma membrane.”

The authors shed light on a less understood cellular signaling aspect: Location-encoded signaling is not restricted to increased protein phosphorylation or to effects mediated by the activity of a cAMP-dependent protein kinase such as protein kinase A, or PKA, in the nucleus. cAMP binds with and activates PKA, which then phosphorylates the protein to elicit cellular reactions.

The study also identified proteins that are dephosphorylated selectively in response to endosome-localized cAMP production and in sequences that do not correspond to PKA consensus sites. “Broadly speaking, our results show that producing cAMP from endosomes has potential to fundamentally ‘re-wire’ downstream cellular signaling by phosphorylation,” von Zastrow said.

The researchers were fascinated to see how multiple proteins are phosphorylated preferentially in response to cAMP produced from endosomes and to see proteins that are dephosphorylated selectively on distinct sites relative to those phosphorylated by PKA. Their cell culture model had tightly controlled variables, so the team cautions against directly extending their results to physiological systems or therapeutics. However, there are potentially profound biomedical implications for future studies.

This collaborative project involved researchers with various backgrounds, and each had different expectations, von Zastrow said. “Dr. Tsvetanova and I would frequently place bets on what results would be obtained. The data was so rich and clear that each one of us was surprised — to the degree that we generally forgot what the original bets were in the first place.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Arti Dumbrepatil

Arti Dumbrepatil is a freelance science writer and communicator. With her academic training plus expertise in science communication and writing, she demystifies and transforms complex, jargon-filled science into enjoyable and comprehensible content that resonates with a diverse audience. She is an ASBMB Today volunteer contributor.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Cholesterol regulatory genes predict liver transplant outcomes
Journal News

Cholesterol regulatory genes predict liver transplant outcomes

April 10, 2026

Researchers identify a link between cholesterol-regulating genes and liver transplant success, which could improve donor screening and patient outcomes.

Lipid signatures for a rare neurological disorder
Journal News

Lipid signatures for a rare neurological disorder

April 10, 2026

Researchers find distinct lipid patterns linked to a rare autoimmune neurological disorder, offering hope for effective targeted therapies for patients.

Disease-linked mutations disrupt protein phase behavior
Journal News

Disease-linked mutations disrupt protein phase behavior

April 9, 2026

Researchers find that pathogenic missense mutations are enriched threefold in phrase-separating intrinsically disordered regions of proteins.

The dual role of asprosin in chronic fatty liver disease
Journal News

The dual role of asprosin in chronic fatty liver disease

April 8, 2026

Researchers uncover a hormone called asprosin that may serve as a potential biomarker for the diagnosis of chronic fatty liver disease and monitoring disease progression.

Novel inhibitor targets RAS-driven cancers
Journal News

Novel inhibitor targets RAS-driven cancers

April 7, 2026

Researchers in Louisville identify a small-molecule drug that blocks RALGEF signaling downstream of mutant RAS. The compound suppresses tumor growth with low toxicity, revealing a new therapeutic strategy for RAS-driven malignancies.

Catching tau in the act
Journal News

Catching tau in the act

April 2, 2026

Using a new proximity-labeling approach, researchers reveal how tangles of the brain-associated protein tau may disrupt RNA biology long before neurons die.